// App-Quantinova.ai

867 : ABT-165 is a first-in-class therapeutic Dual Variable Domain Immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer

Researchers

Presenter

  • Yingchun Li

Principal Investigators

  • Jonathan Hickson

  • Dominic Ambrosi

  • Deanna Haasch

  • Kelly Foster-Duke

  • Lucia Eaton

  • Fang Jiang

  • Surekha Akella

  • Wenqing Gao

  • Sherry Ralston

  • Jijie Gu

  • Susan Morgan-Lappe

Medical Centers

  • AbbVie, Inc., North Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved